Razelle Kurzrock: Time to bridge the artificial divide
Razelle Kurzrock, Founding Director at Michels Rare Cancers Research Laboratories shared a post on X, about a paper by her and colleagues, published in Science Direct.
“Time to bridge the artificial divide. If it’s a solid tumor target, it’s a gene target (and vice versa).
Tissue is not the issue.”
Authors: Jacob Adashek, Javier Munoz, Razelle Kurzrock.
More posts featuring Razelle Kurzrock.
Razelle Kurzrock, MD, is a world-renowned physician-scientist leader in precision medicine and the development of novel therapeutics in the field of oncology.
She is recognized for founding, developing, and chairing one of the largest Phase 1 clinical trial departments globally while at the University of Texas MD Anderson Cancer Center; the central theme of the department was a personalized medicine strategy.
She is also one of the pioneering trialists of the WINTHER precision medicine international trial focusing, for the first time, on transcriptomics in addition to genomics. This trial was the signature study of the Worldwide Innovative Network (WIN) consortium (Nature Medicine).
She also developed and led some of the first tumor-agnostic cancer clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023